ALISPORIVIR - A HOST-TARGETING ANTIVIRAL, PROVIDES LOW VIRAL BREAKTHROUGH RATE AND HIGH BARRIER TO RESISTANCE IN HCV GENOTYPE 1 TREATMENT-NAiVE PATIENTS IN THE PHASE IIB ESSENTIAL STUDY
暂无分享,去创建一个
Christopher T. Jones | A. Vandamme | J. Snoeck | Yanhua Tang | R. Crabbé | W. Bao | Kai Lin | G. Vuagniaux | N. Naoumov | J. Yu | C. Avila | Choilai Tiongyip | Bing Li